Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry

Doping control method for detecting TB-500 (synthetic LKKTETQ from thymosin beta-4) in equine urine and plasma by LC-MS, targeting misuse in horse racing.

Abstract

A veterinary preparation known as TB-500 and containing a synthetic version of the naturally occurring peptide LKKTETQ has emerged.. The peptide segment (17)LKKTETQ(23) is the active site within the protein thymosin β(4) responsible for actin binding, cell migration and wound healing.. The key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus.

Key Findings

TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation. | In order to control the misuse of TB-500 in equine sports, a method to definitely identify its prior use in horses is required. | This study describes a method for the simultaneous detection of N-

Study Design

Research study